About this Journal Submit a Manuscript Table of Contents
Clinical and Developmental Immunology
Volume 2011 (2011), Article ID 614383, 6 pages
http://dx.doi.org/10.1155/2011/614383
Research Article

Humoral Immune Response to Keyhole Limpet Haemocyanin, the Protein Carrier in Cancer Vaccines

1Division of Infectious Diseases, Department of Medicine, Helsinki University Central Hospital, Aurora Hospital, Building 5, 3rd floor, P.O. Box 348, 00029 Helsinki, Finland
2Department of Bacteriology and Immunology, Haartman Institute, FIN-00014 University of Helsinki, Finland
3Departments of Microbiology and Medicine, The University of Alabama at Birmingham, Birmingham, AL 35294-2170, USA
4Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, 12853 Prague 2, Czech Republic
5The University of Alabama at Birmingham, Birmingham, AL 35294, USA
6Department of Medical Microbiology and Immunology, University of Turku, FIN-20520 Turku, Finland

Received 1 January 2011; Revised 16 March 2011; Accepted 30 March 2011

Academic Editor: Bernhard Moser

Copyright © 2011 A. Kantele et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. J. Pollard, K. P. Perrett, and P. C. Beverley, “Maintaining protection against invasive bacteria with protein- polysaccharide conjugate vaccines,” Nature Reviews Immunology, vol. 9, no. 3, pp. 213–220, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. S. F. Slovin, S. J. Keding, and G. Ragupathi, “Carbohydrate vaccines as immunotherapy for cancer,” Immunology and Cell Biology, vol. 83, no. 4, pp. 418–428, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. C. R. Flowers, “BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma,” Expert Review of Vaccines, vol. 6, no. 3, pp. 307–317, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. A. B. Heimberger and J. H. Sampson, “The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients,” Expert Opinion on Biological Therapy, vol. 9, no. 8, pp. 1087–1098, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. L. A. Holmberg and B. M. Sandmaier, “Vaccination with theratope (STn-KLH) as treatment for breast cancer,” Expert Review of Vaccines, vol. 3, no. 6, pp. 655–663, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. S. T. Lee, Y. F. Jiang, K. U. Park, A. F. Woo, and S. S. Neelapu, “BiovaxID: a personalized therapeutic cancer vaccine for non-hodgkin's lymphoma,” Expert Opinion on Biological Therapy, vol. 7, no. 1, pp. 113–122, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. S. S. Neelapu, S. T. Lee, H. Qin, S. C. Cha, A. F. Woo, and L. W. Kwak, “Therapeutic lymphoma vaccines: importance of T-cell immunity,” Expert Review of Vaccines, vol. 5, no. 3, pp. 381–394, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. C. Gatsogiannis and J. Markl, “Keyhole limpet hemocyanin: 9-Å CryoEM structure and molecular model of the KLH1 didecamer reveal the interfaces and intricate topology of the 160 functional units,” Journal of Molecular Biology, vol. 385, no. 3, pp. 963–983, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. J. R. Harris and J. Markl, “Keyhole limpet hemocyanin (KLH): a biomedical review,” Micron, vol. 30, no. 6, pp. 597–623, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Husby, J. Mestecky, Z. Moldoveanu, S. Holland, and C. O. Elson, “Oral tolerance in humans: T cell but not B cell tolerance after antigen feeding,” Journal of Immunology, vol. 152, no. 9, pp. 4663–4670, 1994. View at Scopus
  11. J. Mestecky, S. Husby, Z. Moldoveanu, F. B. Waldo, A. W. L. Van Den Wall Bake, and C. O. Elson, “Induction of tolerance in humans: effectiveness of oral and nasal immunization routes,” Annals of the New York Academy of Sciences, vol. 778, pp. 194–201, 1996. View at Scopus
  12. E. J. Kunkel and E. C. Butcher, “Plasma-cell homing,” Nature Reviews Immunology, vol. 3, no. 10, pp. 822–829, 2003. View at Scopus
  13. H. Sigmundsdottir and E. C. Butcher, “Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking,” Nature Immunology, vol. 9, no. 9, pp. 981–987, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. C. Berlin, E. L. Berg, M. J. Briskin et al., “α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1,” Cell, vol. 74, no. 1, pp. 185–195, 1993. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Camerini, S. P. James, I. Stamenkovic, and B. Seed, “Leu-8/TQ1 is the human equivalent of the Mel-14 lymph node homing receptor,” Nature, vol. 342, no. 6245, pp. 78–82, 1989. View at Scopus
  16. T. K. Kishimoto, M. A. Jutila, and E. C. Butcher, “Identification of a human peripheral lymph node homing receptor: a rapidly down-regulated adhesion molecule,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 6, pp. 2244–2248, 1990. View at Scopus
  17. L. J. Picker, T. K. Kishimoto, C. W. Smith, R. A. Warnock, and E. C. Butcher, “ELAM-1 is an adhesion molecule for skin-homing T cells,” Nature, vol. 349, no. 6312, pp. 796–799, 1991. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. E. L. Berg, T. Yoshino, L. S. Rott et al., “The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1,” Journal of Experimental Medicine, vol. 174, no. 6, pp. 1461–1466, 1991. View at Scopus
  19. A. Kantele, J. Zivny, M. Häkkinen, C. O. Elson, and J. Mestecky, “Differential homing commitments of antigen-specific T cells after oral or parenteral immunization in humans,” Journal of Immunology, vol. 162, no. 9, pp. 5173–5177, 1999. View at Scopus
  20. A. Kantele, J. M. Kantele, E. Savilahti et al., “Homing potentials of circulating lymphocytes in humans depend on the site of activation: oral, but not patenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut,” Journal of Immunology, vol. 158, no. 2, pp. 574–579, 1997. View at Scopus
  21. A. Kantele, E. Savilahti, H. Tiimonen, K. Iikkanen, S. Autio, and J. M. Kantele, “Cutaneous lymphocyte antigen expression on human effector B cells depends on the site and on the nature of antigen encounter,” European Journal of Immunology, vol. 33, no. 12, pp. 3275–3283, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. J. M. Kantele, H. Arvilommi, S. Kontiainen et al., “Mucosally activated circulating human B cells in diarrhea express homing receptors directing them back to the gut,” Gastroenterology, vol. 110, no. 4, pp. 1061–1067, 1996. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Quiding-Järbrink, I. Nordström, G. Granström et al., “Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses,” Journal of Clinical Investigation, vol. 99, no. 6, pp. 1281–1286, 1997.
  24. J. M. Kantele, A. Kantele, and H. Arvilommi, “Circulating immunoglobulin-secreting cells are heterogeneous in their expression of maturation markers and homing receptors,” Clinical and Experimental Immunology, vol. 104, no. 3, pp. 525–530, 1996. View at Scopus
  25. A. Kantele, “Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine,” Vaccine, vol. 8, no. 4, pp. 321–326, 1990. View at Publisher · View at Google Scholar · View at Scopus
  26. J. M. Kantele, E. Savilahti, M. Westerholm-Ormio et al., “Decreased numbers of circulating plasmablasts and differences in IgA1-plasmablast homing to skin in coeliac disease and dermatitis herpetiformis,” Clinical and Experimental Immunology, vol. 156, no. 3, pp. 535–541, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. S. H. Pakkanen, J. M. Kantele, Z. Moldoveanu et al., “Expression of homing receptors on IgA1 and IgA2 plasmablasts in blood reflects differential distribution of IgA1 and IgA2 in various body fluids,” Clinical and Vaccine Immunology, vol. 17, no. 3, pp. 393–401, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. A. Kantele, H. Arvilommi, K. Iikkanen, et al., “Unique characteristics of intestinal immune system as inductor site after antigen re-encounter,” Journal of Infectious Diseases, vol. 191, no. 2, pp. 312–317, 2005.